Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00837031 · ClinicalTrials.gov registry record · Phase 2
Lenalidomide With Gemcitabine in Treatment of Untreated Advanced Carcinoma of the Pancreas
A Phase 2 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
NCT00837031 is a Phase 2 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 72 participants.
The verdict
NCT00837031, a Phase 2 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
Study Summary
To evaluate the 6-month overall survival, safety, and tolerability of lenalidomide in combination with standard gemcitabine as first-line treatment for patients with metastatic pancreatic cancer.
Interventions
- DRUG Lenalidomide
- DRUG Gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2009-02 |
| Est. Completion | 2012-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00837031
The ClinicalTrials.gov registry entry for NCT00837031 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lenalidomide is the first listed.
NCT00837031 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00837031 about?
NCT00837031 is a clinical study titled "Lenalidomide With Gemcitabine in Treatment of Untreated Advanced Carcinoma of the Pancreas". To evaluate the 6-month overall survival, safety, and tolerability of lenalidomide in combination with standard gemcitabine as first-line treatment for patients with metastatic pancreatic cancer.
What is the current status of trial NCT00837031?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2009-02. Estimated completion is 2012-06.
What interventions are being tested in trial NCT00837031?
The interventions under investigation include: Lenalidomide (DRUG), Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT00837031?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.